Dr Reddy s Laboratories Announces Filing of Annual Report on Form 20-F pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Shilpa Medicare share jumps 14% on deal for production of Sputnik V vaccine
The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production
BusinessToday.In | May 17, 2021 | Updated 17:55 IST
Shilpa Medicare share rose 14 per cent to hit an intraday high of Rs 764.45 on BSE today after the company announced that its wholly owned subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a 3-year definitive agreement with Dr. Reddy s Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.
Shilpa Medicare Limited ties up with Dr Reddy S Laboratories Limited for production of Sputnik V Vaccine equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
CARE BBB- rating assigned to proposed NCD issue of Wockhardt Limited
Posted On: 2021-04-06 05:13:59 (Time Zone: Arizona, USA)
CARE Ratings Limited (CARE Ratings) has assigned Wockhardt Limited s proposed Non-Convertible Debenture issue aggregating to Rs. 200 crore a rating of CARE BBB-; Stable (Triple B Minus; Outlook: Stable) .
The rating assigned to proposed non-convertible debenture issue factors in improvement in company s liquidity position post closure of sale of select divisions of domestic formulations business to Dr. Reddy s Laboratories Limited (DRL). The company received Rs. Rs.1483 crore upfront and Rs.67 crore were deposited in Escrow account out of which Rs.54 crore have been credited to WL in Q1FY21 which has improved company s liquidity position over medium term. The rating continues to derive strength from established track record of company in global pharmaceutical industry as well as experienced and resourceful promoters. WL s rating also derive strength
Is Wabtec Corporation (NYSE:WAB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]